Bahrain authorises Covid vaccine for health workers

Galvez is confirmed as vaccine czar

Mexico received on October 30 the doses of the CanSino vaccine to fight Covid-19 to start the Phase 3 clinical trials in which some 15,000 Mexican citizens aged 18 years or over will be vaccinated, the government announced on Tuesday.

She added that the results of studies of the first and second phases of clinical trials of the vaccine; It proved that it is safe and effective without recording any serious symptoms, indicating that the third phase of clinical trials for the same vaccine is now going well.

Amid the coronacrisis, boosting investment would accelerate clinical studies among special populations.

The top two are potential vaccines from the German company Biotech and the United States pharmaceutical company Pfizer and the University of Oxford and AstraZeneca.

USA drug company Pfizer will use its own distribution network for its COVID 19 vaccine instead of going through the US government-appointed coordinator, a company official said. Chinese vaccine maker Sichuan Clover Biopharmaceuticals will receive up to $328 mln from the Coalition for Epidemic Preparedness Innovations (CEPI), an Oslo-based organisation working with the World Health Organization on vaccine access.

Dr. Jaime Montoya, executive director of the Department of Science and Technology-Philippine Council on Health Research and Development told The Manila Times in an e-mail that they will work under Galvez's guidance "to ensure the availability of safe and effective Covid-19 vaccines in the country".

In fact, Clover is the only candidate from mainland China in the group. The COVAX Facility is a global initiative which aims to procure and fairly distribute two billion doses of COVID-19 vaccine by the end of 2021, to help protect the most at-risk groups in all participating countries. "We look forward to continuing our partnership with CEPI as we stay committed to developing a safe and efficacious vaccine for communities in need around the globe".

Related:

Comments


Other news